GeneKey GMP Lab for iNKT Cell Culture

GeneKey Therapeutics is a biotechnology company specializing in the development of invariant Natural Killer T (iNKT) cell therapies for oncology. The company operates a dedicated GMP-compliant laboratory specifically designed for the large-scale culture and engineering of iNKT cells, which are rare immune cells that bridge the innate and adaptive immune systems. Their lead program, GK-001, is an autologous iNKT cell therapy currently in clinical trials for the treatment of various solid tumors. GeneKey's platform focuses on overcoming the natural scarcity of iNKT cells in human blood through proprietary expansion technologies to produce potent, clinical-grade cell products. The company is also advancing a pipeline of Chimeric Antigen Receptor (CAR)-engineered iNKT cells to enhance targeting against specific tumor antigens.